DAEWOONG PHARMA - Company Intelligence Brief

1. Business Overview

Daewoong Pharma is a South Korean pharmaceutical company operating in the healthcare sector. Based on the consolidated financial statements (연결재무제표), the company generates revenue through pharmaceutical operations, though specific business segment detail is not broken out in the provided DART filing data. The company reported total revenues of KRW 1,422.7 billion in fiscal year 2024.

[TRANSLATION NOTE: Business segment descriptions would require access to Korean-language management discussion sections not included in this dataset. The segment detail above reflects only what can be inferred from the financial line items provided.]

2. Financial Trends

Revenue growth has been steady but modest. Sales increased 3.4% year-over-year to KRW 1,422.7 billion in FY2024 from KRW 1,375.3 billion in FY2023, continuing a three-year upward trajectory (FY2022: KRW 1,280.1 billion).

Operating profitability is improving. Operating profit grew 20.7% to KRW 147.9 billion in FY2024 from KRW 122.6 billion in FY2023, representing an operating margin expansion to 10.4% from 8.9%. This suggests improving operational efficiency.

However, net income collapsed 80.5% to just KRW 23.3 billion in FY2024 from KRW 120.0 billion in FY2023, despite stronger operating performance. This dramatic decline appears attributable to non-operating items, as pre-tax income fell 53.6% to KRW 56.6 billion from KRW 122.0 billion.

Debt levels are rising significantly. Total liabilities increased 22.4% to KRW 1,050.0 billion as of December 31, 2024, from KRW 858.0 billion a year earlier. Non-current liabilities more than doubled to KRW 420.6 billion from KRW 162.5 billion, suggesting new long-term financing or capital investments. The debt-to-equity ratio deteriorated to 113% from 94%.

Total assets grew 11.7% to KRW 1,977.0 billion, with non-current assets surging 14.1% to KRW 1,364.2 billion, indicating substantial capital deployment or acquisitions.

3. Ownership Structure

The provided DART filing data contains only financial statement line items and does not include ownership structure details, major shareholder information, or foreign ownership percentages.

[DATA NOT AVAILABLE: Ownership and shareholder information would be found in separate sections of the business report (사업보고서) not included in this dataset.]

4. Key Risks

Profitability volatility from non-operating items: The 80% net income collapse despite 21% operating profit growth reveals dangerous sensitivity to financial costs, foreign exchange, or one-time charges. With non-current liabilities doubling, interest expense pressure may intensify.

Leverage trajectory amid uncertain returns: The company doubled long-term debt while net income plummeted, resulting in a debt-to-equity ratio exceeding 100%. Without visibility into what the KRW 258 billion increase in non-current liabilities is funding, the return on this leverage remains unclear, creating execution risk.

5. Investment Consideration

Daewoong Pharma presents a paradox of operational improvement masked by financial engineering concerns, where accelerating operating margins clash with collapsing net profitability and rapidly rising leverage, requiring clarity on capital allocation before the investment thesis can be assessed.